Axolot Solutions (AXOLOT) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
29 Jul, 2026Executive summary
Focused on expanding in Latin America with pilot installations and customer tests in Mexico and Peru, while supporting the first large-scale AxoPur® installation at Aspa Bruk in Sweden.
The Aspa Bruk project, a key reference for future sales, experienced delays but achieved a successful guarantee run on unbleached pulp; further tests on bleached pulp are planned.
Market interest in AxoPur® remains strong, especially in regions facing water scarcity and stricter environmental regulations.
Financial highlights
Net sales for Q2 2026 were 1,000 tkr, down from 2,240 tkr in Q2 2025, mainly from sales of AxoPur electrodes and reactors.
Operating result for Q2 2026 was -2,868 tkr (Q2 2025: -2,166 tkr); net result per share was -0.01 kr (unchanged year-over-year).
Cash flow from operating activities and investments in Q2 2026 was -4,190 tkr (Q2 2025: -878 tkr); cash and cash equivalents at period end were 13,763 tkr.
Equity at period end was 80,029 tkr, up from 69,829 tkr a year earlier.
Outlook and guidance
Delays in the Aspa Bruk project have slowed decision processes in international projects, but commercial opportunities and interest in AxoPur® are increasing.
The company remains confident in AxoPur®'s commercial potential, supported by promising results from Latin American pilots.
Latest events from Axolot Solutions
- Sales fell and losses widened, but cash strengthened as international expansion accelerates.AXOLOT
Q1 202629 Apr 2026 - Revenue surged in 2025, supported by expansion and key partnerships, despite a net loss.AXOLOT
Q4 202511 Feb 2026 - Sales and operating results improved in Q3 2025, with accelerated international expansion.AXOLOT
Q3 202528 Oct 2025 - Order growth, international expansion, and regulatory tailwinds drive positive Q2 momentum.AXOLOT
Q2 202529 Jul 2025 - Q3 sales surged, but losses deepened as Axolot completed a transformative merger with Mellifiq.AXOLOT
Q3 202413 Jun 2025 - Sales up but losses widen; new funding secured for growth amid rising market demand.AXOLOT
Q2 202413 Jun 2025 - Q1 2025 saw Axolot's sales surge and key PFAS contracts secured via partner expansion.AXOLOT
Q1 20256 Jun 2025 - Strategic shift and major partnership drive Axolot's growth prospects despite 2024 losses.AXOLOT
Q4 20245 Jun 2025